secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001558370-23-012635
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q2 net revenue $134.2M, up 25% YoY; board approves $125M buyback
--------------------------------------------------------------------------------

- Q2 net revenue $134.2M vs $107.0M YoY (+25%); GAAP net income $34.3M ($0.56 diluted EPS).
- Non-GAAP adjusted net income $45.9M ($0.76 diluted EPS) vs $34.7M ($0.57) YoY.
- Average patients on WAKIX ~5,450, up ~350 sequentially; exited Q2 with ~5,600 patients.
- Phase 3 IH INTUNE study fully enrolled; topline data expected Q4 2023. PWS Phase 3 study to initiate Q4 2023.
- Board authorized $125M share repurchase program with no expiration date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/0001558370-23-012635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023012635/hrmy-20230801x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer